EUVIMEDEUVIMED entdecken
Open Access

Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2–Expressing Advanced or Recurrent Uterine Carcinosarcoma (NCCH1615): The STATICE Trial

Tadaaki Nishikawa iD, Kosei Hasegawa iD, Koji Matsumoto iD, Masahiko Mori iD, Yasuyuki Hirashima, Kazuhiro Takehara iD, Kazuya Ariyoshi, Tomoyasu Kato iD, Shigehiro Yagishita, Akinobu Hamada, Mamiko Kawasaki, Satoshi Kawashima iD und 7 weitere

Journal of Clinical Oncology · 20.05.2023 · 41 (15) · 2789-2799

DOI: 10.1200/jco.22.02558 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.05.2023. Verfasst von Tadaaki Nishikawa und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Carcinosarcoma, Immunoconjugates. Die Arbeit wurde bisher 132-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE To investigate the efficacy and safety of trastuzumab deruxtecan, an antibody-drug conjugate targeting human epidermal growth factor receptor 2 (HER2) with a topoisomerase I inhibitor payload, in patients with uterine carcinosarcoma (UCS) expressing HER2. PATIENTS AND METHODS Patients with recurrent UCS with HER2 immunohistochemistry scores ≥1+ previously treated with chemotherapy were included. Patients were assigned to the HER2-high (immunohistochemistry score ≥2+; n = 22) or low (immunohistochemistry score of 1+; n = 10) groups for primary and exploratory analyses, respectively. Trastuzumab deruxtecan 6.4 or 5.4 mg/kg was administered intravenously once every 3 weeks until unacceptable toxicity or disease progression. Dose modification was based on the updated recommended phase II dose for breast cancer to be 5.4 mg/kg. The primary end point was the objective response rate by central review in the HER2-high group. Secondary end points included the overall response rate (ORR) in the HER2-high group by investigator assessment, ORR in the HER2-low group, progression-free survival (PFS), overall survival (OS), and safety. RESULTS The ORR by central review in the HER2-high and HER2-low groups were 54.5% (95% CI, 32.2 to 75.6) and 70.0% (95% CI, 34.8 to 93.3) and those by investigator assessments were 68.2% and 60.0%, respectively. The median PFS and OS in the HER2-high and HER2-low groups were 6.2 and 13.3 months and 6.7 months and not reached, respectively. Grade ≥ 3 adverse events occurred in 20 patients (61%). Grades 1-2 and 3 pneumonitis/interstitial lung disease occurred in eight (24%) and one (3%) patient, respectively. CONCLUSION Trastuzumab deruxtecan has efficacy in patients with UCS, regardless of HER2 status. The safety profile was generally consistent with that previously reported. Toxicities were manageable with appropriate monitoring and treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CarcinosarcomaImmunoconjugatesFemaleHumansAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsErb-b2 Receptor Tyrosine KinasesTrastuzumabUterine NeoplasmsCamptothecin

Substanzen

Antibodies, Monoclonal, HumanizedImmunoconjugatesErb-b2 Receptor Tyrosine KinasesTrastuzumabERBB2 protein, humantrastuzumab deruxtecanCamptothecin

Autor:innen und Institutionen

  • Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Saitama, Japan.
  • Medical Oncology Division, Ambulatory Chemotherapy Center, Hyogo Cancer Center, Hyogo, Japan.
  • Department of Gynecologic Oncology, Aichi Cancer Center Hospital, Aichi, Japan.
  • Division of Gynecology, Shizuoka Cancer Center, Shizuoka, Japan.
  • Department of Gynecologic Oncology, National Hospital Organization Shikoku Cancer Center, Ehime, Japan.

ORCID-Profile: Tadaaki Nishikawa, Kosei Hasegawa, Koji Matsumoto, Masahiko Mori, Kazuhiro Takehara, Tomoyasu Kato, Satoshi Kawashima, Yukari Nagasaka, Hiroshi Yoshida, Kenichi Nakamura, Kan Yonemori

Zitieren

APA

Nishikawa, T., Hasegawa, K., Matsumoto, K., Mori, M., Hirashima, Y., Takehara, K., Ariyoshi, K., Kato, T., Yagishita, S., Hamada, A., Kawasaki, M., Kawashima, S., Tomatsuri, S., Nagasaka, Y., Yoshida, H., Machida, R., Hirakawa, A., Nakamura, K., & Yonemori, K. (2023). Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2–Expressing Advanced or Recurrent Uterine Carcinosarcoma (NCCH1615): The STATICE Trial. Journal of Clinical Oncology, 41(15), 2789-2799. https://doi.org/10.1200/jco.22.02558

Vancouver

Nishikawa T, Hasegawa K, Matsumoto K, Mori M, Hirashima Y, Takehara K, et al. Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2–Expressing Advanced or Recurrent Uterine Carcinosarcoma (NCCH1615): The STATICE Trial. Journal of Clinical Oncology. 2023;41(15):2789-2799. doi:10.1200/jco.22.02558

BibTeX
@article{Nishikawa2023,
  author = {Nishikawa, Tadaaki and Hasegawa, Kosei and Matsumoto, Koji and Mori, Masahiko and Hirashima, Yasuyuki and Takehara, Kazuhiro and Ariyoshi, Kazuya and Kato, Tomoyasu and Yagishita, Shigehiro and Hamada, Akinobu and Kawasaki, Mamiko and Kawashima, Satoshi and Tomatsuri, Sawako and Nagasaka, Yukari and Yoshida, Hiroshi and Machida, Ryunosuke and Hirakawa, Akihiro and Nakamura, Kenichi and Yonemori, Kan},
  title = {Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2–Expressing Advanced or Recurrent Uterine Carcinosarcoma (NCCH1615): The STATICE Trial},
  journal = {Journal of Clinical Oncology},
  year = {2023},
  volume = {41},
  number = {15},
  pages = {2789--2799},
  doi = {10.1200/jco.22.02558}
}
Kostenlos starten →